Drug Manufacturer Teva Ceases Propofol Production Following $500M Award to Hep C Patient

Generic drug manufacturer Teva ceased propofol production three weeks after a jury awarded $500 million to a patient who contracted hepatitis C from a procedure in which he received the anesthetic, according to a Fierce Pharma Manufacturing report.

According to the report, the propofol plant was shut down following "public outcry." Teva is also involved in the case of Anne Arnold, who contracted hepatitis C during a colonoscopy procedure at the Endoscopy Center of Southern Nevada in 2007. The procedure allegedly reused a contaminated jumbo 50-milliliter infusion vial of propofol, intended for long-term sedation rather than short-duration procedures.

The trial involves Teva, as well as drug distributors Baxter International and McKesson. According to law concern Mainor Eglet, the distributors and manufacturer knew that sales of large vials of the drug could lead to the spread of blood-borne diseases.

Teva is facing almost 300 lawsuits stemming from the hepatitis C outbreak.

Related Articles on Anesthesia:
Morphine Could Be Delivered More Easily Through "Pressurized Olfactory Device"
Anesthesiologists, Nurse Anesthetists Must Revalidate Medicare Enrollment Before March 2013
Cholesterol Lowering Drug Reduces Spinal Cord Injury From Surgery

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast